Cour Pharmaceutical Development Company, Inc.

This early-stage clinical trial is testing an investigational drug called CNP-103 in people aged 12-35 who were recently diagnosed with type 1 diabetes. The main goal is to see if the treatment is safe and if it can help protect the body's remaining insulin-producing cells. Resea…